Image

FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort

FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort

Recruiting
All
Phase N/A

Powered by AI

Overview

The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.

Description

The main objective of the STANISLAS cohort is to identify the factors associated with cardiovascular aging (assessed through the study of the degradation of morphological and functional parameters of the heart and vascular systems).

Data (clinical, biological, morphological, genetic and lifestyle) from previous visits (the first having been initiated in the mid-1990s) will be considered as exposure and / or adjustment variables.

The exposure variables of interest will be:

  • The components of metabolic syndrome (MS),
  • Genetic determinants, through an approach of family segregation and candidate genes,
  • Multi-omic biomarkers analyzed from the biological collection of the first assessments of the cohort
  • Food intake, nutrition and eating behavior

The secondary objectives are

  • Identify the factors associated with a degradation of renal parameters (renal function and proteinuria).
  • Identify the factors associated with a degradation of metabolic parameters.
  • To assess the association between SARS-CoV-2 infection (questionnaire and serological approach) and cardiovascular and renal parameters
  • Identify factors associated with the occurrence of clinical cardiovascular events.
  • Association between Covid 19 events and general disabling symptoms
  • Complete the cohort's biological collection for future biomarker assays related to previous objectives

Eligibility

Inclusion Criteria:

  • aged over 18
  • Person who participated in the Stanislas Cohort
  • Person affiliated to a social security scheme or beneficiary of such a scheme
  • Person having received complete information on the organization of the research and having signed an informed consent

Exclusion Criteria:

  • Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1
  • Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health
    Code
    • Pregnant woman, parturient or nursing mother
    • Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
    • Person of full age unable to express consent

Study details
    Cardiovascular Diseases
    Cohort Studies
    Genotype
    Risk Factors
    Nutrition

NCT05916287

Central Hospital, Nancy, France

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.